SCHEMBL2694469

SCHEMBL2694469

CCCN(CCC)CCCCNCc1ccc(NC(=O)N(Cc2ncc[nH]2)Cc2ncc[nH]2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.76
FPR2 P25090 1/20 0.40
RORC P51449 2/20 0.36
LTA4H P09960 1/20 0.36
SCN8A Q9UQD0 1/20 0.35
HDAC6 Q9UBN7 3/20 0.35
HDAC3 O15379 2/20 0.35
HDAC4 P56524 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC7 Q8WUI4 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
HDAC9 Q9UKV0 2/20 0.35
HDAC5 Q9UQL6 2/20 0.35
S1PR1 P21453 3/20 0.35
S1PR3 Q99500 3/20 0.35
S1PR2 O95136 2/20 0.35
S1PR4 O95977 1/20 0.35
HTR5A P47898 1/20 0.35
HDAC10 Q969S8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1793193 0.86 CXCR4 (1.00) CXCR4
SCHEMBL1792747 0.85 CXCR4 (0.98) CXCR4
SCHEMBL1793629 0.85 CXCR4 (0.59) CXCR4HDAC6HDAC3HDAC4HDAC1
SCHEMBL1798332 0.84 CXCR4 (0.84) CXCR4S1PR1S1PR3S1PR2
SCHEMBL1637290 0.83 CXCR4 (0.63) CXCR4FPR2RORCHDAC1HDAC2
SCHEMBL1797198 0.83 CXCR4 (0.94) CXCR4
SCHEMBL1204806 0.82 CXCR4 (0.72) CXCR4
SCHEMBL1637270 0.82 CXCR4 (0.55) CXCR4FPR2RORCNAMPTADRB1
SCHEMBL1795124 0.81 CXCR4 (0.80) CXCR4
SCHEMBL1796026 0.81 CXCR4 (0.76) CXCR4S1PR1S1PR3S1PR2S1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US disclosed
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-08-16 US disclosed
US-8168783-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-05-01 US disclosed
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-07-02 US disclosed
EP-1961744-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885FPR2 283/4885RORC 64/4885
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR3, CXCR1 CXCR4 1/4885FPR2 184/4885RORC 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.